Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer

This article was originally published in The Tan Sheet

Executive Summary

Combined Bayer aspirin, Aleve and Midol sales make firm second-largest analgesic marketer in U.S. and One-A-Day Specialized Blends is top branded herbal product, company tells analysts March 20. Global Consumer Care division sales rose 14.3% to $1.78 bil. in 2000, of which almost half came from North America, Bayer says. Consumer Care growth driven by increased sales of Alka-Seltzer, Bayer aspirin, Phillips' Milk of Magnesia and launch of Aleve Cold & Sinus. PPA-related recall of Alka-Seltzer Plus caused $53.7 mil. charge, in line with expectations (1"The Tan Sheet" Dec. 4, 2000, In Brief). Total worldwide sales grew 13.4% to $28.65 bil. as net income dipped 9.3% to $1.68 bil

Combined Bayer aspirin, Aleve and Midol sales make firm second-largest analgesic marketer in U.S. and One-A-Day Specialized Blends is top branded herbal product, company tells analysts March 20. Global Consumer Care division sales rose 14.3% to $1.78 bil. in 2000, of which almost half came from North America, Bayer says. Consumer Care growth driven by increased sales of Alka-Seltzer, Bayer aspirin, Phillips' Milk of Magnesia and launch of Aleve Cold & Sinus. PPA-related recall of Alka-Seltzer Plus caused $53.7 mil. charge, in line with expectations (1 (Also see "Alka-Seltzer Plus" - Pink Sheet, 4 Dec, 2000.)). Total worldwide sales grew 13.4% to $28.65 bil. as net income dipped 9.3% to $1.68 bil.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel